Monte Rosa Therapeutics (GLUE) Stock Price, Quote, News & History | Benzinga

Monte Rosa Therapeutics Inc (GLUE) Stock Price, Quote, News & History

GLUENASDAQ

Trade with Public

Trade with Public

$15.88

0.171.08%

At close: Aug 7, 5:00 PM EST

$15.88

N/A

After Hours: Aug 7, 4:00 PM EST

Earnings: Q2 2026 Earnings were released on Thu Aug 6th, before the market open

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$15.82

Close

$15.88

Volume / Avg.

1.03M / 1.37M

Day Range

$15.65 - $16.12

52 Wk Range

4.12 - 25.77

Market Cap

$1.35B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

32

Short Interest

20.47%

Days to Cover

13.08

Recent Monte Rosa Therapeutics, Inc. News

Crude Oil Down 2%; ISM Services PMI Surges In December

Avi Kapoor

Monte Rosa's Experimental Drug Slashes Inflammation Linked To Heart Disease

Monte Rosa revealed positive interim Phase 1 data of MRT-8102. Data showed safety, tolerability, and reduction in inflammatory markers.

Vandana Singh

Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday

Avi Kapoor

Why Is Monte Rosa Stock Trading Higher Today?

Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.

Vandana Singh

Dave & Buster's Entertainment Posts Downbeat Results, Joins Adtran Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-24.07M

Investing Cash Flow (TTM)

-316.79M

Financing Cash Flow (TTM)

361.52M

Free Cash Flow (TTM)

-32.08M

Capital Expenditure (TTM)

-8.01M

Net Change in Cash (TTM)

20.66M

Analyst Trends and Forecast

2

Mar

1

May

1

Jun

4

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$774.22M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

51.14

PB Ratio (TTM)

2.79

Earnings Yield % (TTM)

-11.00%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$5.71

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$90.10M

Debt to Equity

0.08

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$15.82

Close

$15.88

Volume / Avg.

1.03M / 1.37M

Day Range

$15.65 - $16.12

52 Wk Range

4.12 - 25.77

Market Cap

$1.35B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

32

Short Interest

20.47%

Days to Cover

13.08

About

Sector

Health Care

Industry

Biotechnology

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degra...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Monte Rosa Therapeutics (GLUE) stock?

A

You can purchase shares of Monte Rosa Therapeutics (NASDAQ:GLUE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Monte Rosa Therapeutics (GLUE) competitors?

A

Other companies in Monte Rosa Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Monte Rosa Therapeutics (GLUE) stock?

A

Monte Rosa Therapeutics has a consensus price target of $23.38.

Q

What is the current price for Monte Rosa Therapeutics (GLUE)?

A

The stock price for Monte Rosa Therapeutics (NASDAQ: GLUE) is $15.88 last updated August 7, 2026 at 4:00 PM EDT.

Q

Does Monte Rosa Therapeutics (GLUE) pay a dividend?

A

There are no upcoming dividends for Monte Rosa Therapeutics.

Q

When is Monte Rosa Therapeutics (NASDAQ:GLUE) reporting earnings?

A

Monte Rosa Therapeutics does not have any upcoming earnings scheduled.

Q

Is Monte Rosa Therapeutics (GLUE) going to split?

A

There is no upcoming split for Monte Rosa Therapeutics.

Q

What sector and industry does Monte Rosa Therapeutics (GLUE) operate in?

A

Monte Rosa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.